Form 4: Athira Pharma Director Barbara Kosacz Acquires Stock Options
SEC Form 4 Filing
Director Barbara Kosacz acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024.
Summary
- On May 24, 2024, Barbara Kosacz, a director of Athira Pharma, Inc., acquired 20,900 stock options.
- The exercise price of these options is $2.64.
- The options vest on the earlier of May 24, 2025, or the day before the next annual meeting of the Issuer's stockholders after May 24, 2024.
- The options expire on May 23, 2034.
- Following the transaction, Kosacz directly owns 20,900 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment. This is a routine filing related to stock option grants to a director.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's common for directors to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/24/2024 | Date of transaction: Barbara Kosacz acquired stock options. |
| 05/24/2025 | Vesting date of the stock options (or earlier if the next annual meeting occurs before this date). |
| 05/23/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.